$HOOK: Hookipa Soars on FDA OK of Early Stage Trial For Cancer Treatment

Date: Thursday, July 11th, 2019

Stock(s) mentioned:

Source: TheStreet (https://www.thestreet.com)

Summary: Preliminary study of company’s TheraT treatment expected to start in second half of 2019.

Full article address: https://www.thestreet.com/investing/stocks/hookipa-soars-on-fda-ok-of-early-stage-trial-for-cancer-treatment-15017473

Related News:

$HOOK $ALKS $EXEL $GILD $AMGN: Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer’s Study

$HOOK: What’s So Great About Hookipa Pharma’s HPV Cancer Treatment

$HOOK $MCRN: 28 Stocks Moving In Friday’s Pre-Market Session

$HOOK: Hookipa on go with study of HB-201 in HPV+ cancers; shares up 37 …

$HOOK $IIPR: Hookipa, EMCORE Making Big Moves In Thursday’s After-Hours …

$HOOK $GILD $VBIV $MRNA $MRK $GSK: 5 things to know about Hookipa Pharma ahead of its IPO

Latest News:

$BIIB: Biogen Rises on Strong Second-Quarter Earnings, Guidance Boost

$HOG: Harley Davidson second-quarter sales continued to slide as profit falls 19%

$VYM: What If the Fed Does Cut Rates and It’s Already Totally Priced In?

$PEBO: Peoples Bancorp Inc. Declares Quarterly Dividend

$IRDM: Iridium Announces Second-Quarter 2019 Results; Reaffirms 2019 …

$F: Ford to invest another $50 million in its Chicago operations, create …

$PYPL: Why PayPal Stock Could Have a Strong Earnings Season

$UBS: UBS Q2 global wealth profit rises, i-banking fals

$AVY: Avery Dennison tightened FY2019 guidance

$MSFT: Microsoft Caps Off an Amazing 2019. Here’s Why It Can Repeat in …

$HXL: More on Hexcel’s Q2 results; raises FY19 EPS guidance